Login
$AVTX
$7.43 -$0.33 (4.25%) Live

$AVTX SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G
10 Nov 2026 SCHEDULE 13G
06 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shar...

05 Nov 2026 S-3ASR
05 Nov 2026 424B5
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

WAYNE, Pa., Nov. 5, 2026 – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial re...

29 Oct 2026 SCHEDULE 13G
02 Oct 2026 Form 4: Jain Rita, Director

Granted 1,322 Stock Option (Right to Buy) ($16.2K)

02 Oct 2026 Form 4: Lind Kevin Robert, Director

Granted 1,352 Stock Option (Right to Buy) ($16.6K)

02 Oct 2026 Form 4: Philip Ron M, Director

Granted 1,109 Stock Option (Right to Buy) ($13.6K)

18 Sep 2026 Form 4: Sullivan Christopher Ryan, Chief Financial Officer

Received 12,394 shares by exercise or conversion ($122K) · Sold 12,394 shares ($202K)

11 Sep 2026 Form 4: Sullivan Christopher Ryan, Chief Financial Officer

Received 10,185 shares by exercise or conversion ($81.9K) · Sold 10,185 shares ($179K)

01 Sep 2026 Form 4: Doyle Mittie, Chief Medical Officer

Received 679 shares by exercise or conversion ($5.46K) · Sold 679 shares ($13.6K)

19 Aug 2026 Form 4: Sullivan Christopher Ryan, Chief Financial Officer

Received 40,821 shares by exercise or conversion ($403K) · Sold 41,694 shares ($828K) · Received 31,031 shares by exercise or conversion ($307K) · 1 more

19 Aug 2026 Form 4: Doyle Mittie, Chief Medical Officer

Received 1,000 shares by exercise or conversion ($12.7K) · Sold 1,000 shares ($20K)

18 Aug 2026 144
17 Aug 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support